Do not apply Lokoid® to the periorbital area due to the risk of developing glaucoma. With systematic exposure to conjunctiva, there is a risk of increased intraocular pressure.
With pronounced lichenification, dryness, hyperkeratosis, it is better to prefer Lokoid in the form of an ointment or Lipocream.
The drug is not desirable to use in the presence of atrophic skin changes.
The risk of local and systemic side effects increases when applied to extensive areas of damage, prolonged use, the use of occlusion and in childhood.
If there is no effect within 2 weeks of continuous treatment, the diagnosis should be clarified.
As with any glucocorticosteroid drug, it is desirable to limit the duration of application and the course dose is minimal enough to stop the skin process.
Pediatric use:
Possible use in children from 6 months of age. In cases of use of the drug in children, on the face area or under occlusive dressings, the duration of the course of treatment should be reduced.
When used in children, the skin surface area on which the drug is applied should not exceed 20% of the total.
In childhood, suppression of the function of the adrenal cortex can develop faster. In addition, there may be a decrease in the excretion of growth hormone. When using the drug for a long time, it is necessary to observe the body weight, growth, plasma cortisol level. In a study in children who received 30-60 g of Lokoid per week for 4 weeks compared to 1% hydrocortisone ointment, no child showed any adrenocortical dysfunction, while the difference between hydrocortisone 17-butyrate in this indicator from the usual hydrocortisone was not observed.